316 related articles for article (PubMed ID: 33992830)
1. The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials.
Prodromidou A; Lekka S; Fotiou A; Psomiadou V; Iavazzo C
J Gynecol Obstet Hum Reprod; 2021 Nov; 50(9):102164. PubMed ID: 33992830
[TBL] [Abstract][Full Text] [Related]
2. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
3. [The long-term efficacy of metformin in megestrol acetate-based fertility-sparing treatment for patients with endometrial atypical hyperplasia and endometrioid endometrial cancer].
Dong YT; Guan J; Yang BY; Yierfulati G; Xue Y; Chen XJ
Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):729-735. PubMed ID: 38462352
[No Abstract] [Full Text] [Related]
4. New therapeutic approaches for the fertility-sparing treatment of endometrial cancer.
Mitsuhashi A; Shozu M
J Obstet Gynaecol Res; 2020 Feb; 46(2):215-222. PubMed ID: 32017321
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
6. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
7. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis.
Chu D; Wu J; Wang K; Zhao M; Wang C; Li L; Guo R
BMC Cancer; 2018 Apr; 18(1):438. PubMed ID: 29669520
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract][Full Text] [Related]
10. Fertility-sparing management for endometrial cancer: review of the literature.
Garzon S; Uccella S; Zorzato PC; Bosco M; Franchi MP; Student V; Mariani A
Minerva Med; 2021 Feb; 112(1):55-69. PubMed ID: 33205638
[TBL] [Abstract][Full Text] [Related]
11. Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial.
Petchsila K; Prueksaritanond N; Insin P; Yanaranop M; Chotikawichean N
Asian Pac J Cancer Prev; 2020 Mar; 21(3):733-741. PubMed ID: 32212801
[TBL] [Abstract][Full Text] [Related]
12. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
[TBL] [Abstract][Full Text] [Related]
13. Conservative management of grade 2 stage IA endometrial carcinoma and literature review.
Shan W; Wu P; Yang B; Zhang H; Sun L; Lv Q; Luo X; Cheng Y; Zhu Q; Chen X
J Obstet Gynaecol Res; 2021 Mar; 47(3):984-991. PubMed ID: 33403812
[TBL] [Abstract][Full Text] [Related]
14. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Acosta-Torres S; Murdock T; Matsuno R; Beavis AL; Stone RL; Wethington SL; Levinson K; Grumbine F; Ferriss JS; Tanner EJ; Fader AN
Gynecol Oncol; 2020 May; 157(2):348-356. PubMed ID: 32085863
[TBL] [Abstract][Full Text] [Related]
15. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Dominick S; Hickey M; Chin J; Su HI
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
[TBL] [Abstract][Full Text] [Related]
16. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of metformin treatment in endometrial cancer: a meta-analysis.
Gong H; Chen Y; Zhou D
Pharmazie; 2020 Aug; 75(8):401-406. PubMed ID: 32758341
[No Abstract] [Full Text] [Related]
18. The role of prolonged progestin treatment and factors predicting successful fertility-sparing treatment for early endometrial endometrioid adenocarcinoma.
Ou YC; Fu HC; Lan J; Wu CH; Kung FT; Lan KC; Tsai YC; Lin H
Eur J Obstet Gynecol Reprod Biol; 2021 Dec; 267():99-104. PubMed ID: 34739876
[TBL] [Abstract][Full Text] [Related]
19. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
20. The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial.
Tehranian A; Ghahghaei-Nezamabadi A; Arab M; Khalagi K; Aghajani R; Sadeghi S
J Gynecol Obstet Hum Reprod; 2021 Jun; 50(6):101863. PubMed ID: 32652300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
